UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer
Rhea-AI Summary
UroGen (Nasdaq: URGN) launched the LG-UTUC Luminaries initiative on April 8, 2026 to recognize clinicians and institutions showing leadership in low-grade upper tract urothelial cancer care.
The program highlights guideline-aligned, kidney-sparing approaches and names Dr. Saum Ghodoussipour as the inaugural honoree.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – URGN
On the day this news was published, URGN gained 5.93%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.3% during that session. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $56M to the company's valuation, bringing the market cap to $1.00B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Phase 3 data | Positive | -1.0% | ENVISION Phase 3 ZUSDURI results with strong 24‑month durability data. |
| Mar 13 | Advocacy survey news | Neutral | -1.9% | BCAN report on bladder cancer recurrence burden and patient fears. |
| Mar 06 | Inducement grants | Neutral | -2.7% | RSU inducement grants to new employees under Nasdaq Rule 5635(c)(4). |
| Mar 02 | Earnings and outlook | Negative | -12.3% | 2025 results with $109.8M revenue but $153.5M net loss and higher expenses. |
| Mar 02 | Loan refinancing | Neutral | -12.3% | Refinanced term loan up to $250M at fixed 8.25% interest. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent URGN news, including positive clinical and financial milestones, has often been followed by negative price reactions.
Over recent months, UroGen has reported several key developments. On Mar 2, 2026, it posted full-year $109.8M revenue alongside a $153.5M net loss and a refinanced $250M term loan, with shares falling about 12%. Phase 3 ENVISION data and ZUSDURI results published on Mar 30, 2026 also preceded a modest decline. Advocacy and survey-related news, as well as inducement RSU grants, saw smaller negative moves. Against this backdrop, today’s clinician-recognition initiative continues a pattern of non-revenue news amid a still-challenged share price.
Regulatory & Risk Context
Key Terms
upper tract urothelial cancer medical
endoscopic medical
kidney-sparing medical
urothelial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the launch of its “LG-UTUC Luminaries” initiative, recognizing clinicians and institutions demonstrating leadership, expertise, and a commitment to advancing low‑grade upper tract urothelial cancer (LG‑UTUC) care.
LG‑UTUC is a rare form of cancer affecting an estimated 6,000-7,000 patients each year in the U.S., which represents approximately
“Through the LG-UTUC Luminaries initiative, we are honored to recognize the clinicians and institutions redefining what is possible for patients living with LG-UTUC,” said Liz Barrett, President and Chief Executive Officer of UroGen. “By elevating these leaders, we aim to inspire broader adoption of evidence-based, kidney-sparing care, strengthen collaboration across the urology community, and accelerate progress toward a future where patients with this highly recurrent disease have better outcomes and a better care experience.”
The LG-UTUC Luminaries initiative recognizes clinicians and institutions working to achieve excellence in LG-UTUC care. Honorees have extensive experience with LG-UTUC and are actively involved in treatment, research, and peer-to-peer education. Institutional recipients are distinguished by established, guideline-aligned care pathways spanning diagnosis, treatment, and long-term surveillance, as well as strong commitments to physician training, research participation, and comprehensive patient support.
UroGen recognizes Saum Ghodoussipour, MD, Director, Bladder and Urothelial Cancer Program, Rutgers Cancer Institute, and Associate Professor of Surgery, Rutgers Robert Wood Johnson Medical School, as the first recipient of this flagship LG-UTUC Luminaries recognition—an honor that will continue to be presented to physicians and institutions dedicated to helping shape the future of kidney-sparing management in LG-UTUC.
“I’m truly honored to receive this recognition,” said Dr. Saum Ghodoussipour, Director of the Bladder and Urothelial Cancer Program at Rutgers Cancer Institute and Associate Professor of Surgery at Rutgers Robert Wood Johnson Medical School, NJ. “This distinction reflects the dedication of our entire multidisciplinary team at Rutgers Cancer Institute, whose commitment to advancing education, research, and patient-centered care continues to drive progress for individuals living with LG-UTUC. I’d especially like to recognize Dr. Vignesh Packiam, Director of Clinical and Translational Research in Urologic Oncology and Associate Professor of Surgery at Rutgers Robert Wood Johnson Medical School, whose leadership and contributions have been instrumental in shaping our program. Together, we remain committed to improving outcomes through collaboration, innovation, and a steadfast focus on our patients.”
About the LG-UTUC Luminaries Initiative
The LG-UTUC Luminaries initiative is UroGen’s effort to recognize and collaborate with leading clinicians and institutions advancing care for patients with low-grade upper tract urothelial cancer. By highlighting clinical leadership and fostering collaboration across the urology community, the initiative supports continued progress in kidney-sparing care and efforts to improve outcomes in this rare and highly recurrent disease.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X, @UroGenPharma.
INVESTOR CONTACT:
Vincent Perrone
vincent.perrone@urogen.com
(609) 460-3588 Ext. 1093
MEDIA CONTACT:
Cindy Romano
Cindy.romano@urogen.com
(609) 460-3566 Ext. 1083
